Simacort

Anti-inflammation, allergy, RA, acute rheumatic fever, bronchial asthma, allergic rhinitis, dermatoses, acute bursitis, sprue, uveitis & blood dyscrasia.

Adult & ped weighing >60 lbs Initially 8-32 mg daily. Reduce dose by 2 mg every 2-3 days until lowest dose is reached. Ped weighing <60 lbs 4-12 mg daily.

Should be taken with food.

History of hypersensitivity. Systemic fungal infection. Concomitant use w/ live or attenuated virus vaccines.

Hypersensitivity. Not to be used in patients w/ systemic fungal infection, unless necessary. Patients w/ peptic ulcer or duodenal ulcer, diabetes, TB or viral infections; cirrhosis; diverticulitis; hypothyroidism; HTN; myasthenia gravis; ocular herpes simplex; osteoporosis. Psychotic tendencies may be aggravated. May increase incidence of secondary infection, mask acute infection (including fungal infection), prolong or exacerbate viral infections. Edema in the presence of renal disease. W/draw therapy gradually. Renal insufficiency. Pregnancy & lactation.

HTN; atrophic skin condition, impaired wound healing; Cushing's syndrome, decreased body growth; GIT disorder, loss of appetite; osteoporosis; depression, euphoria. Hyperglycemia, primary adrenocortical insufficiency; cataract, glaucoma; pulmonary TB.

Enhanced adverse/toxic effect of acetylcholinesterase inhibitors; deferasirox; leflunomide; loxapine; natalizumab; nicorandil; NSAIDs; quinolone antibiotics; live vaccines. Diminished neoplastic effect of aldesleukin. Increased metabolism w/ aminoglutethimide. Enhanced hypokalemic effect of amphotericin B; thiazide diuretics. Enhanced fluid-retaining effect of androgens. Diminished therapeutic effect of antidiabetic agents; BCG; calcitriol; corticorelin; hyaluronidase; sipuleucel-T; urea cycle disorder agents; inactivated vaccines. Increased serum conc w/ aprepitant; strong CYP3A4 inhibitors; estrogen derivatives; fosaprepitant; mifepristone; telaprevir. Enhanced hyperglycemic effect of ceritinib. Diminished diagnostic effect of Coccidioides immitis skin test. Decreased serum conc w/ strong CYP3A4 inducers; mitotane. Enhanced adverse/toxic effect w/ denosumab; pimecrolimus; ritonavir; salicylates; topical tacrolimus. Diminished therapeutic effect w/ echinacea; mifepristone. Enhanced hypokalemic effect w/ indacaterol. Decreased serum conc of INH; telaprevir. Enhanced adverse neuromuscular effect w/ non-depolarizing neuromuscular blocking agents. Enhanced immunosuppressive effect w/ roflumilast. Enhanced immunosuppressive effect of tofacitinib. Enhanced neutropenic effect w/ trastuzumab. Enhanced anticoagulant effect of warfarin.

Corticosteroid Hormones

H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

S